ZBD(SH:603567) 智通财经网·2025-12-02 11:18Core Viewpoint - The company, Zhenbao Island (603567.SH), announced that its wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration, indicating a significant development in its pharmaceutical offerings [1] Group 1 - The approved drug is indicated for the treatment of various conditions including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and several types of infections [1] - The drug is specifically approved for use in adults aged 18 and older, expanding the company's product portfolio in the pharmaceutical market [1] - The conditions treated by the drug include non-complicated and complicated skin and soft tissue infections, complicated intra-abdominal infections, plague, and mild to moderate pelvic inflammatory disease without associated tubo-ovarian or pelvic abscess [1]